Table 4. mRNA of relevant genes in the heart of ACS-transgenic mice 7 days after treatment with AdCMV-β-gal or AdCMV-leptin and in untreated wild type.
| 7 days of hyperleptinemia
|
|||||
|---|---|---|---|---|---|
| ACS-transgenic mice
|
|||||
| mRNA | Wild type (n = 4) | P | AdCMV-β-gal (n = 4) | P | AdCMV-leptin (n = 4) |
| ACC1 | 1 ± 0.06 | 2.15 ± 0.68 | 1.48 ± 0.32 | ||
| ACC2 | 1 ± 0.02 | 1.10 ± 0.22 | 0.79 ± 0.10 | ||
| ACO | 1 ± 0.20 | 2.00 ± 0.87 | 1.67 ± 0.43 | ||
| CPT-1 | 1 ± 0.02 | 1.30 ± 0.03 | 1.30 ± 0.08 | ||
| FAS | 1 ± 0.09 | <0.05 | 3.24 ± 0.09 | <0.05 | 1.11 ± 0.12 |
| GPAT | 1 ± 0.14 | <0.05 | 1.57 ± 0.07 | <0.01 | 0.87 ± 0.14 |
| PPARα | 1 ± 0.25 | 1.10 ± 0.26 | <0.01 | 0.59 ± 0.18 | |
| PPARγ | 1 ± 0.14 | 1.10 ± 0.32 | 1.03 ± 0.17 | ||
| SPT | 1 ± 0.19 | 1.73 ± 0.51 | 1.07 ± 0.22 | ||
| PGC-1α | 1 ± 0.21 | 2.75 ± 0.17 | 1.69 ± 0.18 | ||
| SREBP-1c | 1 ± 0.40 | 1.00 ± 0.40 | 1.25 ± 0.15 | ||
| CD36 | 1 ± 0.64 | 0.86 ± 0.30 | 1.04 ± 0.30 | ||
| MCD | 1 ± 0.46 | <0.05 | 1.87 ± 0.21 | <0.05 | 0.93 ± 0.13 |
| SCD-1 | 1 ± 0.10 | 2.98 ± 1.01 | 3.14 ± 1.07 | ||
| SCD-4 | 1 ± 0.30 | 3.00 ± 1.80 | 3.00 ± 1.50 | ||
| Bax | 1 ± 0.12 | 1.89 ± 0.82 | 0.92 ± 0.51 | ||
| Bcl2 | 1 ± 0.33 | 1.41 ± 0.10 | 3.00 ± 1.50 | ||
| SIRT1 | 1 ± 0.33 | 1.43 ± 0.44 | 1.11 ± 0.10 | ||
| UCP-1 | 1 ± 0.29 | 1.20 ± 0.65 | 0.77 ± 0.31 | ||
| UCP-2 | 1 ± 0.24 | 1.20 ± 0.01 | 1.35 ± 0.24 | ||
| UCP-3 | 1 ± 0.04 | 1.39 ± 0.42 | 0.66 ± 0.22 | ||
mRNA of each gene listed in Table 1 was measured by real-time PCR using 18S as the invariant control in all. mRNAs that were unchanged or that were not biologically relevant are not shown. Data are expressed as fold change from the level in wild-type control. Each value represents the mean ± SEM of four mice. Abbreviations are as indicated in Table 1.